Cytoreg®, a novel cancer therapy from Venezuela receives International Health Prize

Sept. 18, 2011 - PRLog -- The International Health Federation (CIS), recognized Cytorex de Venezuela, S.A. with the prize named “World Healthcare Leaders”, during its V Congress, which took place in Cartagena, Colombia in September 1 and 2, 2011.

Cytorex de Venezuela, S.A is a 100% Venezuelan corporation which has been working in the last few years with local scientists and researchers in the development of its novel and proprietary US patented technology  named Cytoreg®, aimed to help cancer patients. Currently. the project is in a preclinical stage.

Mr. William Jiménez,  Cytorex de Venezuela’s Executive Vice-President and CEO, attended the event, and presented a conference in which he outlined the progress of the Cytoreg(R) project  providing detailed information in relation with the preclinical R&D plan, currently in full execution. Mr. Jiménez thanked CIS for the recognition given to the company and its technology.
What is Cytorex?

Cytorex de Venezuela, S.A. is a Maracaibo, Venezuela based Biopharmaceutical Company involved in research and development (R&D) of therapeutic agents for the treatment of Cancer, and also for diseases of auto-immune origin.
In 2005, the company received the Venezuelan IDEAS in prize recognition of its novel advancements in science and its business plan.

Cytoreg®, the company’s lead compound is currently in preclinical development for several cancer indications, as well as in the discovery phase for diseases of auto-immune origin, where it has shown early promise.

The objective of Cytorex de Venezuela, S.A. is to introduce to the market new compounds based on its US patented technology, which provides for the first-in-time pharmacological use of combination of acids in the treatment of high impact malignancies in humans such as:  Cancer, Lupus, arthritis, scleroderma, diabetes, Parkinson’s and Alzheimer’s.

Since August 2010, Cytorex de Venezuela S.A executes an R&D agreement with the University of  Los Andes (ULA) located in Merida. The agreement includes complementary testing to numerous assays, already preformed in the United States, in the areas of Pharmacology. Toxicology,  Efficacy in animal models, as well as determination of new mechanisms of action of Cytoreg®. Scientists from other Venezuelan institutions such as Universidad of Zulia (LUZ), The Venezuela Institute of Scientific Research (IVIC), the Experimental Biology Institute from the Venezuelan Central University (UCV), in collaboration with  American institutions such as: Florida Atlantic University (FAU) and  University South Florida (USF) are also active participants.
The importance of the prize given by the CIS to Cytorex de Venezuela, S.A. relies in the fact that is Venezuela Company the recipient of such honor, in recognition to the fact that that Cytorex de Venezuela, S.A. is pioneer in the invention development of therapies to treat cancer in the history of medicine in Venezuela.

Cytorex de Venezuela S.A, together with its US based affiliate company  Cytorex Biosciences Inc., estimate that during 2012 or early 2013, they will be ready to file for an IND (Investigational New Drug) with regulatory authorities in any Latin American country and/or with the United States Food and Drug Administration, in the indications of Glioblastoma Multiforme (Brian Cancer), Pancreatic Cancer and/or Breast Cancer.

For additional information please contact:

In Venezuela: Cytorex de Venezuela, S.A,  William Jiménez, EVP & CEO | +58 414 614 0226 | wjimenez@cytorex.com

In USA: Cytorex Biosciences Inc., Carlos M. Garcia, Managing Director & COO | +1 954 573 4006 | cmgarcia@cytorex.com